Compare · DFTX vs MDWD
DFTX vs MDWD
Side-by-side comparison of Definium Therapeutics Inc. (DFTX) and MediWound Ltd. (MDWD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DFTX and MDWD operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $2.57B, about 14.1x MDWD ($182.2M).
- MDWD has been more active in the news (5 items in the past 4 weeks vs 3 for DFTX).
- MDWD has more recent analyst coverage (8 ratings vs 4 for DFTX).
- Company
- Definium Therapeutics Inc.
- MediWound Ltd.
- Price
- $23.56-4.23%
- $14.19-1.05%
- Market cap
- $2.57B
- $182.2M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2014
- News (4w)
- 3
- 5
- Recent ratings
- 4
- 8
MediWound Ltd.
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MWPC005, a topically applied biological drug candidate that is in Phase I/II clinical trial for the treatment of non-melanoma skin cancers; and MWPC003 for connective tissue disorders. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
Latest DFTX
- Definium Therapeutics Announces New Employee Inducement Grants
- Definium Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
- Definium Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Definium Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorder
- Definium Therapeutics Announces New Employee Inducement Grants
- SEC Form 10-Q filed by Definium Therapeutics Inc.
- Definium Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Definium Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
- Definium Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026
Latest MDWD
- Director Shamir Nachum bought $83,996 worth of Ordinary Shares (6,000 units at $14.00), increasing direct ownership by 12% to 55,815 units (SEC Form 4)
- Director Fox David Morton bought $49,901 worth of Ordinary Shares (3,537 units at $14.11), increasing direct ownership by 19% to 22,283 units (SEC Form 4)
- Director Rubinstein Samuel bought $2,150 worth of Ordinary Shares (150 units at $14.33), increasing direct ownership by 5% to 2,993 units (SEC Form 4)
- SEC Form 6-K filed by MediWound Ltd.
- MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update
- SEC Form SCHEDULE 13G filed by MediWound Ltd.
- MediWound to Report First Quarter 2026 Financial Results
- SEC Form 6-K filed by MediWound Ltd.
- Newly Published U.S. Expert Consensus Aligns with MediWound's Strategy for Chronic Wound Debridement
- MediWound to Present New EscharEx® Data at Leading Wound Care Conferences